BACKGROUND: Dexrazoxane may reduce anthracycline-associated cardiotoxicity in pediatric cancer patients. However, concerns of secondary acute myeloid leukemia (AML) have led to restrictions on pediatric dexrazoxane use in Europe. Published data about dexrazoxane-associated secondary AML are limited and conflicting. We sought to estimate the secondary AML risk in children receiving dexrazoxane after anthracycline exposure. PROCEDURE: A retrospective cohort of children with newly identified malignancies (excluding AML) receiving anthracyclines between January 1, 1999 and March 31, 2011 was established using the Pediatric Health Information System (PHIS). Patients were followed for all subsequent admissions to identify dexrazoxane exposures and secondary AML, defined by AML ICD-9 codes and AML induction chemotherapy. Logistic regression was used to model the association of dexrazoxane and secondary AML risk. A propensity score was used to adjust for measurable confounding. RESULTS: Of 15,532 patients in the cohort exposed to anthracyclines, 1,406 received dexrazoxane. The secondary AML rate was 0.21% (3 of 1,046) in dexrazoxane-exposed and 0.55% (77 of 14,126) in unexposed patients. In a propensity score-adjusted multivariate analysis, dexrazoxane exposure was not associated with an increased risk of secondary AML, OR = 0.38, 95% CI 0.11-1.26. CONCLUSIONS: Dexrazoxane was not associated with an increased risk of secondary AML in a large cohort of pediatric cancer patients receiving anthracyclines in US hospitals. While these data support dexrazoxane's safety in the general pediatric oncology population, additional studies are needed to confirm these findings and to quantify dexrazoxane's long-term cardioprotective effects.
BACKGROUND:Dexrazoxane may reduce anthracycline-associated cardiotoxicity in pediatric cancerpatients. However, concerns of secondary acute myeloid leukemia (AML) have led to restrictions on pediatric dexrazoxane use in Europe. Published data about dexrazoxane-associated secondary AML are limited and conflicting. We sought to estimate the secondary AML risk in children receiving dexrazoxane after anthracycline exposure. PROCEDURE: A retrospective cohort of children with newly identified malignancies (excluding AML) receiving anthracyclines between January 1, 1999 and March 31, 2011 was established using the Pediatric Health Information System (PHIS). Patients were followed for all subsequent admissions to identify dexrazoxane exposures and secondary AML, defined by AML ICD-9 codes and AML induction chemotherapy. Logistic regression was used to model the association of dexrazoxane and secondary AML risk. A propensity score was used to adjust for measurable confounding. RESULTS: Of 15,532 patients in the cohort exposed to anthracyclines, 1,406 received dexrazoxane. The secondary AML rate was 0.21% (3 of 1,046) in dexrazoxane-exposed and 0.55% (77 of 14,126) in unexposed patients. In a propensity score-adjusted multivariate analysis, dexrazoxane exposure was not associated with an increased risk of secondary AML, OR = 0.38, 95% CI 0.11-1.26. CONCLUSIONS:Dexrazoxane was not associated with an increased risk of secondary AML in a large cohort of pediatric cancerpatients receiving anthracyclines in US hospitals. While these data support dexrazoxane's safety in the general pediatric oncology population, additional studies are needed to confirm these findings and to quantify dexrazoxane's long-term cardioprotective effects.
Authors: Elvira C van Dalen; Helena J H van der Pal; Wouter E M Kok; Huib N Caron; Leontien C M Kremer Journal: Eur J Cancer Date: 2006-09-20 Impact factor: 9.162
Authors: Cameron K Tebbi; Wendy B London; Debra Friedman; Doojduen Villaluna; Pedro A De Alarcon; Louis S Constine; Nancy Price Mendenhall; Richard Sposto; Allen Chauvenet; Cindy L Schwartz Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Wendy Landier; Smita Bhatia; Debra A Eshelman; Katherine J Forte; Teresa Sweeney; Allison L Hester; Joan Darling; F Daniel Armstrong; Julie Blatt; Louis S Constine; Carolyn R Freeman; Debra L Friedman; Daniel M Green; Neyssa Marina; Anna T Meadows; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Kathleen S Ruccione; Charles A Sklar; Melissa M Hudson Journal: J Clin Oncol Date: 2004-12-02 Impact factor: 44.544
Authors: S E Lipshultz; S R Lipsitz; S M Mone; A M Goorin; S E Sallan; S P Sanders; E J Orav; R D Gelber; S D Colan Journal: N Engl J Med Date: 1995-06-29 Impact factor: 91.245
Authors: Elly V Barry; Lynda M Vrooman; Suzanne E Dahlberg; Donna S Neuberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Eric C Larsen; Albert Moghrabi; Yvan Samson; Marshall A Schorin; Harvey J Cohen; Steven E Lipshultz; Stephen E Sallan; Lewis B Silverman Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: L H Wexler; M P Andrich; D Venzon; S L Berg; L Weaver-McClure; C C Chen; V Dilsizian; N Avila; P Jarosinski; F M Balis; D G Poplack; M E Horowitz Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544
Authors: Cindy L Schwartz; Leonard H Wexler; Mark D Krailo; Lisa A Teot; Meenakshi Devidas; Laurel J Steinherz; Allen M Goorin; Mark C Gebhardt; John H Healey; Judith K Sato; Paul A Meyers; Holcombe E Grier; Mark L Bernstein; Steven E Lipshultz Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: Kelly D Getz; Lillian Sung; Todd A Alonzo; Kasey J Leger; Robert B Gerbing; Jessica A Pollard; Todd Cooper; E Anders Kolb; Alan S Gamis; Bonnie Ky; Richard Aplenc Journal: J Clin Oncol Date: 2020-04-28 Impact factor: 44.544
Authors: Aarti Asnani; Baohui Zheng; Yan Liu; You Wang; Howard H Chen; Anita Vohra; An Chi; Ivan Cornella-Taracido; Huijun Wang; Douglas G Johns; David E Sosnovik; Randall T Peterson Journal: JCI Insight Date: 2018-01-11
Authors: Steven E Lipshultz; Melissa B Diamond; Vivian I Franco; Sanjeev Aggarwal; Kasey Leger; Maria Verônica Santos; Stephen E Sallan; Eric J Chow Journal: Paediatr Drugs Date: 2014-10 Impact factor: 3.022
Authors: Sara Vandenwijngaert; Melissa Swinnen; Ann-Sophie Walravens; Manu Beerens; Hilde Gillijns; Ellen Caluwé; Robert E Tainsh; Daniel I Nathan; Kaitlin Allen; Peter Brouckaert; Jozef Bartunek; Marielle Scherrer-Crosbie; Kenneth D Bloch; Donald B Bloch; Stefan P Janssens; Emmanuel S Buys Journal: Antioxid Redox Signal Date: 2016-09-08 Impact factor: 8.401